赵欣彤, 李天磊, 张文轩*, 吴松*. 铁离子载体-抗生素偶联物的研究进展J. 药学学报, 2021,56(11): 3004-3013. doi: 10.16438/j.0513-4870.2021-0410
引用本文: 赵欣彤, 李天磊, 张文轩*, 吴松*. 铁离子载体-抗生素偶联物的研究进展J. 药学学报, 2021,56(11): 3004-3013. doi: 10.16438/j.0513-4870.2021-0410
ZHAO Xin-tong, LI Tian-lei, ZHANG Wen-xuan*, WU Song*. Research progress on siderophore-antibiotic conjugatesJ. Acta Pharmaceutica Sinica, 2021,56(11): 3004-3013. doi: 10.16438/j.0513-4870.2021-0410
Citation: ZHAO Xin-tong, LI Tian-lei, ZHANG Wen-xuan*, WU Song*. Research progress on siderophore-antibiotic conjugatesJ. Acta Pharmaceutica Sinica, 2021,56(11): 3004-3013. doi: 10.16438/j.0513-4870.2021-0410

铁离子载体-抗生素偶联物的研究进展

Research progress on siderophore-antibiotic conjugates

  • 摘要: 随着细菌耐药特别是革兰阴性细菌耐药趋势的不断上升,耐药细菌的感染已成为临床最难解决的问题之一。基于“特洛伊木马”策略设计的铁载体-抗生素偶联物,可以通过主动摄取穿过革兰阴性细菌的外膜,有望成为临床抗感染治疗的有力武器。本文回顾了近年来报道的铁载体-抗生素偶联物药物设计策略,并重点探讨了不同类型的抗生素在此策略中的使用。

     

    Abstract: With the increasing drug resistance of bacteria, especially Gram-negative bacteria, the infection of drug-resistant bacteria has become one of the most challengeable clinical problems. The siderophore-antibiotic conjugates based on the "Trojan horse" strategy can penetrate the extracellular membrane of Gram-negative bacteria by active transport, and they are expected to become a powerful weapon for clinical anti-infection treatment. This review describes the drug design strategies of siderophore-antibiotic conjugates reported in recent years, and focuses on the use of different types of antibiotics in this strategy.

     

/

返回文章
返回